Search research articles
Contact Us
Filters
Showing results (31-40 of 70) with videos related to
Page
of 7
Sort By:
Journal of Pharmacological Sciences
|
February 24, 2006
QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation
Hiroyasu Miyazaki, Hiroyuki Watanabe, Tetsuya Kitayama, et al.
Journal of Diabetes Investigation
|
April 1, 2018
Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
Ikuro Matsuba, Ren Matsuba, Shun Ishibashi, et al.
Journal of Clinical and Experimental Hepatology
|
April 9, 2026
<i>Post Hoc</i> Analysis of a Phase 2 Randomized Trial of Pemafibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: Associations With Platelet Count, Liver Stiffness, and Spleen Volume
Ryohei Tanigawa, Rohit Loomba, Yuichiro Eguchi, et al.
Atherosclerosis
|
April 11, 2016
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
Shun Ishibashi, Shizuya Yamashita, Hidenori Arai, et al.
Therapeutic Innovation & Regulatory Science
|
June 20, 2019
Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan
Kentaro Sakamaki, Seitaro Yoshida, Yusuke Morita, et al.
Therapeutic Innovation & Regulatory Science
|
April 20, 2021
Evaluation of Data Errors and Monitoring Activities in a Trial in Japan Using a Risk-Based Approach Including Central Monitoring and Site Risk Assessment
Hidenobu Kondo, Tomoaki Kamiyoshihara, Kenji Fujisawa, et al.
Journal of Atherosclerosis and Thrombosis
|
May 28, 2025
Effects of Pemafibrate on Cholesterol Synthesis and Absorption: a Post-Hoc Subgroup Analysis of a Phase 2 Clinical Trial
Shizuya Yamashita, Eiichi Araki, Hidenori Arai, et al.
Advances in Therapy
|
June 18, 2023
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, et al.
Journal of Atherosclerosis and Thrombosis
|
September 25, 2024
Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia-A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover study
Shizuya Yamashita, Eiichi Araki, Hidenori Arai, et al.
Journal of Atherosclerosis and Thrombosis
|
April 14, 2024
Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial
Hidenori Arai, Shizuya Yamashita, Eiichi Araki, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 70) with videos related to
Sort By:
Page
of 7
Journal of Pharmacological Sciences
|
February 24, 2006
QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation
Hiroyasu Miyazaki, Hiroyuki Watanabe, Tetsuya Kitayama, et al.
Journal of Diabetes Investigation
|
April 1, 2018
Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
Ikuro Matsuba, Ren Matsuba, Shun Ishibashi, et al.
Journal of Clinical and Experimental Hepatology
|
April 9, 2026
<i>Post Hoc</i> Analysis of a Phase 2 Randomized Trial of Pemafibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: Associations With Platelet Count, Liver Stiffness, and Spleen Volume
Ryohei Tanigawa, Rohit Loomba, Yuichiro Eguchi, et al.
Atherosclerosis
|
April 11, 2016
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
Shun Ishibashi, Shizuya Yamashita, Hidenori Arai, et al.
Therapeutic Innovation & Regulatory Science
|
June 20, 2019
Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan
Kentaro Sakamaki, Seitaro Yoshida, Yusuke Morita, et al.
Therapeutic Innovation & Regulatory Science
|
April 20, 2021
Evaluation of Data Errors and Monitoring Activities in a Trial in Japan Using a Risk-Based Approach Including Central Monitoring and Site Risk Assessment
Hidenobu Kondo, Tomoaki Kamiyoshihara, Kenji Fujisawa, et al.
Journal of Atherosclerosis and Thrombosis
|
May 28, 2025
Effects of Pemafibrate on Cholesterol Synthesis and Absorption: a Post-Hoc Subgroup Analysis of a Phase 2 Clinical Trial
Shizuya Yamashita, Eiichi Araki, Hidenori Arai, et al.
Advances in Therapy
|
June 18, 2023
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, et al.
Journal of Atherosclerosis and Thrombosis
|
September 25, 2024
Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia-A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover study
Shizuya Yamashita, Eiichi Araki, Hidenori Arai, et al.
Journal of Atherosclerosis and Thrombosis
|
April 14, 2024
Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial
Hidenori Arai, Shizuya Yamashita, Eiichi Araki, et al.
Page
of 7